Analyst Ratings for Regeneron Pharmaceuticals Inc. (REGN)Updated: 2017-07-28
Analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have given it a consensus rating of Overweight. A consensus rating of Overweight was previously issued for REGN last month.
Of the 24 analysts covering the stock, 10 gave it a buy rating, 1 issued an overweight rating, 13 gave a hold rating, 0 gave an underweight rating, and 0 gave a sell rating. Compared to three months ago, there has been an decrease of 3 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.
Several price targets were given for REGN by the analysts covering the stock. The most optimistic analyst gave a price target of 593, implying potential capital gains of 16.64 percent. The most pessimistic analyst gave a price target of 327, implying potential capital losses of -35.68 percent. Some investors take price targets and stock ratings with a grain of salt, knowing that some analysts can have indirect business with the stocks they cover.
In the last 30 days, analysts have changed their quarterly earnings estimates upwards by an average of 0.48 percent. This can be compared with the average change in earnings estimates over the past 3 months, which is -0.14 percent. On the other hand, earnings estimates for the fiscal year have been revised upwards by 0.39 percent, as compared to a month ago. If we look at the last 90 days instead, we find a net average change of 0.77 percent in FY estimates.
Investors like to see analysts making revisions in the same direction, as that raises confidence in the revisions. 1 analysts made positive revisions to their quarterly estimates over the past month, while 0 analysts revised their estimates downwards. Also over the last month, 1 analysts increased their estimates for the FY earnings, while 0 analysts decreased their estimates.
Analysts estimate earnings of REGN to grow at a rate of 24.83 percent. People on Wall Street often look at a company's PEG ratio. Investors like to see smaller values for the PEG ratio, because people typically see that as an indicator of higher growth relative to stock price. Wall Street investors typically prefer a PEG ratio to be smaller than 1, but many choose to perform ratio comparisons with other companies in the industry. REGN has a PEG ratio of 2.46.
In the trailing 52-weeks, REGN hit 543.55 at the highest peak, while it's lowest trading point was 325.35. Today's price is 56.27 percent above the 52-week low, and below the high by 6.46 percent. REGN has a P/E ratio of 61.18. Investors typically compare the P/E ratio to a company's peers in the industry. The REGN value stock report compares REGN to some of its peers using value stock charts. The market cap of REGN is $54.81 billion. REGN's next earnings release will be on 0000-00-00, which is days away.